"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 4 | 5 |
| 2005 | 0 | 5 | 5 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 8 | 10 |
| 2009 | 2 | 8 | 10 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 9 | 9 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 8 | 8 |
| 2014 | 3 | 13 | 16 |
| 2015 | 5 | 10 | 15 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 11 | 13 |
| 2019 | 7 | 4 | 11 |
| 2020 | 4 | 8 | 12 |
| 2021 | 2 | 7 | 9 |
| 2022 | 1 | 8 | 9 |
| 2023 | 1 | 5 | 6 |
| 2024 | 4 | 5 | 9 |
| 2025 | 4 | 3 | 7 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Malignant peripheral nerve sheath tumors: a report from Children's Oncology Group study ARST0332. J Natl Cancer Inst. 2026 May 01; 118(5):829-838.
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
-
Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. Pediatr Blood Cancer. 2026 May; 73(5):e70228.
-
Comparison of the Cytotoxicity, Internalization and Anti-Cancer Drug Delivery Efficacy of Nature Killer Cell Derived Nanovesicles and Extracellular Vesicles. Int J Nanomedicine. 2025; 20:10683-10700.
-
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat. 2025 Nov; 214(1):69-77.
-
Targeted activation of Nrf2 at sites of oxidative stress reverses doxorubicin-induced cognitive impairments in mice. Brain Behav Immun. 2025 Oct; 129:547-556.
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Doxorubicin-induced phosphorylation of lamin A/C enhances DNMT1 and activates cardiomyocyte death via suppressing GATA-4 and Bcl-xL in rat heart. Biochim Biophys Acta Mol Basis Dis. 2025 03; 1871(3):167692.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 01 07; 15(1):1061.